Page 8 - ஸ்பானிஷ் தேசிய புற்றுநோய் ஆராய்ச்சி மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
New approach may lead to novel treatments for renal fibrosis
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Open door to treatment of renal fibrosis by showing that it is caused by telomere shortening
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Share
The University of Glasgow will play a key role in a new pan European consortium, using artificial intelligence to improve treatments for pancreatic cancer.
PANCAIM will improve treatment for pancreatic cancer patients, utilising tools such as artificial intelligence, integrated genomics and medical imaging. Dr David Chang from the Institute of Cancer Sciences will lead the work for the University of Glasgow, and will bring a wealth of experience in precision medicine in pancreatic cancer.
Pancreatic Cancer
PANCAIM is a four year Horizon 2020 funded project, and is a partnership between the University of Glasgow, the Karolinska Institute, Radboud University in the Netherlands, the Spanish National Cancer Research Centre, Oslo University Hospital, and industry partners, Siemens, SMEs Collective Minds Radiology, The Hyve and is project managed by Amires.
Study opens the door to new possibilities targeting telomeres to help treat cancer
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: When TRF1 is phosphorylated by AKT, telomeres are normal (top); in the cell lines where AKT doesn t modify TRF1, telomeres are shorter and have a lower potential to generate tumours. view more
Credit: PLOS Genetics
The Telomeres and Telomerase Group led by Maria A. Blasco at the Spanish National Cancer Research Centre (CNIO) continues to make progress in unravelling the role that telomeres -the ends of chromosomes that are responsible for cellular ageing as they shorten- play in cancer. The CNIO team was among the first to propose that shelterins, proteins that wrap around telomeres and act as a protective shield, might be therapeutic targets for cancer treatment. Subsequently, they found that eliminating one of these shelterins, TRF1, blocks the initiation and progression of lung cancer and glioblastoma in mouse models and prevents glioblastoma stem cells from forming secondary tumours. Now, in a study published in